Genitourinary Syndrome of Menopause

Valadares, Ana Lúcia Ribeiro; Kulak, Jaime; Nasser, Elizabeth Jeha; Silva, Célia Regina da; Nahás, Eliana Aguiar Petri; Baccaro, Luiz Francisco; Albernaz, Marco Aurélio; Wender, Maria Celeste Osório; Mendes, Maria Célia; Dardes, Rita de Cássia de Maio; Strufaldi, Rodolfo; Bocardo, Rogerio Cesar; Pompei, Luciano de Melo

doi:10.1055/s-0042-1748463

Cited by 3 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the perception of discomfort a woman feels can translate into different symptoms. However, this condition finds a common basis in its manifestations in local irritation due to mucosal atrophy, infection, or inflammation [ 1 ]. Moreover, since the vagina is a self-protecting system, the establishment of alterations leading to genitourinary syndrome results in a vicious circle destined to worsen the symptomatology.…”

Section: Discussionmentioning

confidence: 99%

“…Genitourinary syndrome, previously defined as vulvovaginal atrophy, manifests with signs and symptoms deriving from estrogen diminution in the female genitourinary tract. This syndrome results in both genital dysfunctions, such as dryness, dyspareunia, burning, and irritation, and urinary dysfunctions, such as dysuria, nocturia, urgency, and recurrent urinary tract infections [ 1 ]. Vaginitis is a common condition occurring during women’s lives that can be caused by infective or inflammatory processes or following an alteration in the normal vaginal microbiota [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stable Ozonides plus Vitamin E Acetate (Ozoile) for Treatment of Genitourinary Syndrome

Ronsini,

Iavarone,

Lacerenza

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Genitourinary syndrome, previously defined as vulvovaginal atrophy, manifests with signs and symptoms deriving from estrogen diminution in the female genitourinary tract. Stable ozonides are derivatives of artemisinin found to be stable against strong basic and acidic conditions. Vitamin E is an important antioxidant diminishing the output of reactive oxygen species in the oxidation of fats and the emanation of free radicals, reducing cellular injury and aging. The primary aim of the present study was to assess the positive effects of an ozonide plus a vitamin E acetate-based compound (Ozoil-E) on genitourinary syndrome symptom relief after a maximum of 20 days of treatment. Materials and Methods: The inclusion criteria for patients’ enrollment were women of child-bearing age or in menopause reporting genitourinary syndrome’s related symptoms, such as pain, burning, a bad smell, dyspareunia, dryness, itching, bleeding, and nervousness. The exclusion criteria were Sjogren’s syndrome and patients administered retinoic acid, an agent that causes mucosal dryness. Participants completed a questionnaire before and after 20 days of treatment. Results: The incidence of pain decreased from 16.7% to 11.8% (p-value < 0.0001). In addition, the mean symptom intensity decreased from 2.10 to 0.87 (p-value < 0.0001). Dryness was the most frequent pre-treatment symptom and decreased from 85.5% to 53.8% (p-value < 0.0001) (mean: 2.21 vs. 0.90; p-value < 0.0001). Conclusions: Ozoil-E was effective in reducing most gynecologic symptoms related to genitourinary syndrome. However, further studies are needed to compare its effect with other standards of care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Stable Ozonides plus Vitamin E Acetate (Ozoile) for Treatment of Genitourinary Syndrome

Ronsini,

Iavarone,

Lacerenza

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Marija Nemunytė, Nikita Petrauskaitė, Darius Trumbeckas Lietuvos sveikatos mokslų universitetas, Medicinos fakultetas simptomų. Šis sindromas, anksčiau vadintas vulvovagininė atrofija, susijęs su sparčiai mažėjančiu estrogeno kiekiu genitourinariniuose takuose [2]. Mažėjantis estrogeno kiekis paveikia šlapimo takus, įskaitant šlapimo pūslę ir šlaplę, todėl daugeliui moterų išsivysto šlapimo nelaikymas.…”

Section: šLapimo Nelaikymas Po Menopauzėsunclassified

Šlapimo Nelaikymas Po Menopauzės

Nemunytė,

Petrauskaitė,

Trumbeckas

2024

Health Sciences

View full text Add to dashboard Cite

Šlapimo nelaikymas po menopauzės paveikia nuo 15 iki 35 proc. moterų po menopauzės. Dažnai suvokiamas kaip natūrali senėjimo pasekmė, šlapimo nelaikymas neigiamai veikia įvairius moters gyvenimo aspektus. Šiame straipsnyje nagrinėjami šlapimo nelaikymo po menopauzės etiologija, rizikos veiksniai, tipai ir gydymo būdai. Įtampos šlapimo nelaikymas, susijęs su susilpnėjusiais dubens dugno raumenimis, gali būti gydomas keičiant gyvenimo būdą, taikant vietinę estrogenų terapiją, naudojant makšties prietaisus, šlaplės tūrį didinančias medžiagas ir atliekant chirurgines intervencijas, tokias kaip vidurinės šlaplės raiščio implantacija. Skubos šlapimo nelaikymas, kuriam būdingas per didelis detrusoriaus aktyvumas, gali būti gydomas elgesio terapija ir medikamentais, įskaitant anticholinerginius vaistus arba beta-3 adrenoreceptorių agonistus. Gydymui atspariais atvejais gali būti svarstomi trečios eilės metodai, tokie kaip sakralinio nervo neuromoduliacija arba onabotulinum toxin A injekcijos. Siekiant optimizuoti menopauzės šlapimo nelaikymo gydymo rezultatus, labai svarbu suteikti pacientėms informaciją apie įvairias gydymo galimybes, pritaikytas individualiems poreikiams.

show abstract

Study on the Effect of the Vaginal Administration of Conjugated Estrogens Cream Combined with Progesterone on the Endometrium of Rats and Its Mechanism of Action

Li,

Xiao,

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The purpose of this study was to investigate the impact of conjugated estrogen cream, in conjunction with progesterone, on the endometrium, following vaginal administration, and assess the combined dose–effect relationship with progesterone. Initially, bilateral ovaries from mature, female, Sprague Dawley rats were excised to establish a hypoestrogenic (perimenopausal) model. A conjugated estrogen–progesterone combination cream was administered vaginally for a duration of 12 days. Subsequently, this study used pathological sections, Enzyme-Linked Immunosorbent Assay (ELISA) for pharmacodynamic studies, network pharmacology to explore possible signalling pathways associated with the drug and menopausal syndrome, and partial validation using a real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (ICH). The results demonstrate that, relative to the model group, the conjugated estrogen monotherapy significantly increased the uterine weight coefficients (p < 0.0001) and endometrial thickness (p < 0.001) and upregulated the expression of Cyclin D1 and VEGF. Moreover, this treatment downregulated PTEN expression. The co-administration of progesterone reversed these effects in a dose-dependent manner. Overall, the vaginal administration of a combination of progesterone and conjugated estrogen cream demonstrated the ability to mitigate endometrial hyperplasia induced by conjugated estrogen vaginal cream monotherapy. Furthermore, the effect of progesterone exhibited a dose-dependent response.

show abstract

Genitourinary Syndrome of Menopause

Cited by 3 publications

References 31 publications

Stable Ozonides plus Vitamin E Acetate (Ozoile) for Treatment of Genitourinary Syndrome

Stable Ozonides plus Vitamin E Acetate (Ozoile) for Treatment of Genitourinary Syndrome

Šlapimo Nelaikymas Po Menopauzės

Study on the Effect of the Vaginal Administration of Conjugated Estrogens Cream Combined with Progesterone on the Endometrium of Rats and Its Mechanism of Action

Contact Info

Product

Resources

About